229 related articles for article (PubMed ID: 21072045)
21. Asparaginase use for the treatment of acute lymphoblastic leukemia.
Barba P; Dapena JL; Montesinos P; Rives S
Med Clin (Barc); 2017 Mar; 148(5):225-231. PubMed ID: 28118965
[No Abstract] [Full Text] [Related]
22. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.
Rajić V; Debeljak M; Goričar K; Jazbec J
Leuk Lymphoma; 2015; 56(11):3103-8. PubMed ID: 25697915
[TBL] [Abstract][Full Text] [Related]
24. PEG-linked asparaginase marketed.
Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
[No Abstract] [Full Text] [Related]
25. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
26. Catalyzing improvements in ALL therapy with asparaginase.
Marini BL; Perissinotti AJ; Bixby DL; Brown J; Burke PW
Blood Rev; 2017 Sep; 31(5):328-338. PubMed ID: 28697948
[TBL] [Abstract][Full Text] [Related]
27. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
28. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
29. Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia.
Parma M; Belotti D; Pogliani EM
Haematologica; 1996; 81(2):191. PubMed ID: 8641657
[No Abstract] [Full Text] [Related]
30. L-asparaginase-induced apoptosis in ALL cells involves IP
Vervliet T; Parys JB
Cell Calcium; 2019 Nov; 83():102076. PubMed ID: 31491643
[TBL] [Abstract][Full Text] [Related]
31. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
32. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
[TBL] [Abstract][Full Text] [Related]
33. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
Su N; Pan YX; Zhou M; Harvey RC; Hunger SP; Kilberg MS
Pediatr Blood Cancer; 2008 Feb; 50(2):274-9. PubMed ID: 17514734
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
35. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
36. High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?
Kamen BA
J Pediatr Hematol Oncol; 2004 Jun; 26(6):333-5. PubMed ID: 15167344
[No Abstract] [Full Text] [Related]
37. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.
Cory JG; Cory AH
In Vivo; 2006; 20(5):587-9. PubMed ID: 17091764
[TBL] [Abstract][Full Text] [Related]
38. The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?
Pinheiro JP; Boos J
Br J Haematol; 2004 Apr; 125(2):117-27. PubMed ID: 15059133
[No Abstract] [Full Text] [Related]
39. Escherichia coli-asparaginase (Elspar) is superior to Erwinia-asparaginase (Erwinase) in childhood acute lymphoblastic leukaemia (ALL) induction--an early response study using minimal residual disease (MRD) markers.
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Ann Acad Med Singap; 2004 Sep; 33(5 Suppl):S45-6. PubMed ID: 15651203
[No Abstract] [Full Text] [Related]
40. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
Ramakers-van Woerden NL; Pieters R; Loonen AH; Hubeek I; van Drunen E; Beverloo HB; Slater RM; Harbott J; Seyfarth J; van Wering ER; Hählen K; Schmiegelow K; Janka-Schaub GE; Veerman AJ
Blood; 2000 Aug; 96(3):1094-9. PubMed ID: 10910927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
